228 related articles for article (PubMed ID: 33288590)
1. Elective Nodal Irradiation for Non-small Cell Lung Cancer Complicated With Chronic Obstructive Pulmonary Disease Affects Immunotherapy Αfter Definitive Chemoradiotherapy.
Morimoto M; Nishino K; Wada K; Imamura F; Konishi K; Kuhara H; Tamiya M; Inoue T; Kunimasa K; Kimura M; Hirata T; Kanayama N; Toratani M; Kawachi H; Ohira K; Nakanishi E; Ohira S; Sagawa T; Miyazaki M; Matsunaga T; Kumagai T; Teshima T
Anticancer Res; 2020 Dec; 40(12):6957-6970. PubMed ID: 33288590
[TBL] [Abstract][Full Text] [Related]
2. A randomized study of involved-field irradiation versus elective nodal irradiation in combination with concurrent chemotherapy for inoperable stage III nonsmall cell lung cancer.
Yuan S; Sun X; Li M; Yu J; Ren R; Yu Y; Li J; Liu X; Wang R; Li B; Kong L; Yin Y
Am J Clin Oncol; 2007 Jun; 30(3):239-44. PubMed ID: 17551299
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Toxicity Between Intensity-Modulated Radiotherapy and 3-Dimensional Conformal Radiotherapy for Locally Advanced Non-small-cell Lung Cancer.
Ling DC; Hess CB; Chen AM; Daly ME
Clin Lung Cancer; 2016 Jan; 17(1):18-23. PubMed ID: 26303127
[TBL] [Abstract][Full Text] [Related]
4. Toxicity Related to Radiotherapy Dose and Targeting Strategy: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Locally Advanced Non-Small Cell Lung Cancer.
Schild SE; Fan W; Stinchcombe TE; Vokes EE; Ramalingam SS; Bradley JD; Kelly K; Pang HH; Wang X
J Thorac Oncol; 2019 Feb; 14(2):298-303. PubMed ID: 30292852
[TBL] [Abstract][Full Text] [Related]
5. Elective nodal irradiation or involved-field irradiation in definitive chemoradiotherapy for esophageal squamous cell cancer: a retrospective analysis in clinical N0 patients.
Sun Y; Zhang XL; Mao QF; Liu YH; Kong L; Li MH
Curr Oncol; 2018 Oct; 25(5):e423-e429. PubMed ID: 30464693
[TBL] [Abstract][Full Text] [Related]
6. Comparison between the effects of elective nodal irradiation and involved-field irradiation on long-term survival in thoracic esophageal squamous cell carcinoma patients: A prospective, multicenter, randomized, controlled study in China.
Lyu J; Yisikandaer A; Li T; Zhang X; Wang X; Tian Z; Chen L; Lu B; Chen H; Yang J; Wang Q; Zhang J; Ma Y; Liu R; Liu R; Hage A; Lang J
Cancer Med; 2020 Oct; 9(20):7460-7468. PubMed ID: 32841543
[TBL] [Abstract][Full Text] [Related]
7. Radiation recall pneumonitis triggered by an immune checkpoint inhibitor following re-irradiation in a lung cancer patient: a case report.
Ye X; Yang J; Stebbing J; Peng L
BMC Pulm Med; 2022 Feb; 22(1):54. PubMed ID: 35123465
[TBL] [Abstract][Full Text] [Related]
8. Immune-Related Pneumonitis After Chemoradiotherapy and Subsequent Immune Checkpoint Blockade in Unresectable Stage III Non-Small-Cell Lung Cancer.
Naidoo J; Nishino M; Patel SP; Shankar B; Rekhtman N; Illei P; Camus P
Clin Lung Cancer; 2020 Sep; 21(5):e435-e444. PubMed ID: 32576443
[TBL] [Abstract][Full Text] [Related]
9. Elective nodal irradiation (ENI) vs. involved field radiotherapy (IFRT) for locally advanced non-small cell lung cancer (NSCLC): A comparative analysis of toxicities and clinical outcomes.
Fernandes AT; Shen J; Finlay J; Mitra N; Evans T; Stevenson J; Langer C; Lin L; Hahn S; Glatstein E; Rengan R
Radiother Oncol; 2010 May; 95(2):178-84. PubMed ID: 20356642
[TBL] [Abstract][Full Text] [Related]
10. Immune Checkpoint Inhibitor Outcomes for Patients With Non-Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications.
Ricciuti B; Dahlberg SE; Adeni A; Sholl LM; Nishino M; Awad MM
J Clin Oncol; 2019 Aug; 37(22):1927-1934. PubMed ID: 31206316
[TBL] [Abstract][Full Text] [Related]
11. Association between intensity modulated radiotherapy and survival in patients with stage III non-small cell lung cancer treated with chemoradiotherapy.
Koshy M; Malik R; Spiotto M; Mahmood U; Rusthoven CG; Sher DJ
Lung Cancer; 2017 Jun; 108():222-227. PubMed ID: 28625640
[TBL] [Abstract][Full Text] [Related]
12. [Involved-field three-dimensional conformal radiation treatment for stage III non-small-cell lung].
Yu JM; Sun XD; Li MH; Zhang JD; Yao CP; Liu S; Zhang Z
Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):526-9. PubMed ID: 17147119
[TBL] [Abstract][Full Text] [Related]
13. Potential for reduced toxicity and dose escalation in the treatment of inoperable non-small-cell lung cancer: a comparison of intensity-modulated radiation therapy (IMRT), 3D conformal radiation, and elective nodal irradiation.
Grills IS; Yan D; Martinez AA; Vicini FA; Wong JW; Kestin LL
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):875-90. PubMed ID: 14529795
[TBL] [Abstract][Full Text] [Related]
14. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
[TBL] [Abstract][Full Text] [Related]
15. The role of involved field irradiation versus elective nodal irradiation in definitive radiotherapy or chemoradiotherapy for esophageal cancer- a systematic review and meta-analysis.
Wang H; Song C; Zhao X; Deng W; Shen W
Front Oncol; 2022; 12():1034656. PubMed ID: 36408184
[TBL] [Abstract][Full Text] [Related]
16. Outcome and toxicity of intensity modulated radiotherapy with simultaneous integrated boost in locally advanced non-small cell lung cancer patients.
Fondevilla Soler A; López-Guerra JL; Dzugashvili M; Sempere Rincón P; Sautbaet A; Castañeda P; Díaz JM; Praena-Fernandez JM; Rivin Del Campo E; Azinovic I
Clin Transl Oncol; 2017 Dec; 19(12):1469-1477. PubMed ID: 28589434
[TBL] [Abstract][Full Text] [Related]
17. [Clinical outcomes of different irradiation ranges in definitive intensity-modulated radiotherapy for esophageal cancer].
Zhu SC; Li QF; Zhang XY; Deng WZ; Song CY; Wang X; Yan K
Zhonghua Zhong Liu Za Zhi; 2020 Dec; 42(12):1040-1047. PubMed ID: 33342161
[No Abstract] [Full Text] [Related]
18. A population-based study of primary chemoradiotherapy in clinical stage III non-small cell lung cancer: intensity-modulated radiotherapy versus 3D conformal radiotherapy.
Hsia TC; Tu CY; Chen HJ; Chen SC; Liang JA; Chen CY; Wang YC; Chien CR
Anticancer Res; 2014 Sep; 34(9):5175-80. PubMed ID: 25202111
[TBL] [Abstract][Full Text] [Related]
19. Influence of conformal radiotherapy technique on survival after chemoradiotherapy for patients with stage III non-small cell lung cancer in the National Cancer Data Base.
Sher DJ; Koshy M; Liptay MJ; Fidler MJ
Cancer; 2014 Jul; 120(13):2060-8. PubMed ID: 24692108
[TBL] [Abstract][Full Text] [Related]
20. Is selective nodal irradiation in non-small cell lung cancer still safe when using IMRT? Results of a prospective cohort study.
Martinussen HM; Reymen B; Wanders R; Troost EG; Dingemans AC; Öllers M; Houben R; De Ruysscher D; Lambin P; van Baardwijk A
Radiother Oncol; 2016 Nov; 121(2):322-327. PubMed ID: 27884510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
